Oxytocin vs PT-141

Oxytocin

Oxytocin is a nine-amino-acid posterior pituitary hormone and, unlike most compounds in this dataset, an approved medicine: Pitocin and Syntocinon are licensed for obstetric use, given by titrated intravenous infusion to induce or augment labour and by IV or IM injection to control postpartum bleeding. PREGNANCY IS A HARD CONTRAINDICATION HERE, AND NOT AS A PRECAUTION. Oxytocin's approved pharmacological action is to make the uterus contract. Taken off-label by someone who is or might be pregnant, it risks uterine hyperstimulation, fetal distress, miscarriage or preterm labour. Legitimate obstetric use happens in a hospital with continuous fetal and contraction monitoring and the ability to stop the infusion within minutes; none of that exists around a self-administered wellness dose. Do not use this if pregnancy is possible. THE OBSTETRIC LABEL DOSING IS NOT TRANSFERABLE TO THE RANGE ON THIS PAGE, and the two must never be mixed. The label is expressed in USP units and delivered as a continuous IV infusion titrated in milliunits per minute against uterine response, or as a bolus IM dose after delivery. That is a different route, a different unit, a different endpoint and a different setting. No obstetric figure was used to build the range below, and a label dose read in units must not be entered here as micrograms - the international standard is roughly 1.68 mcg of peptide per IU, so units and micrograms are not interchangeable numbers. This entry also omits the IV and IM routes on purpose: they are the approved obstetric routes and are not what this tool models. The range here comes only from the intranasal social-cognition literature, where acute single doses of roughly 16-40 IU have been used and 24 IU is the conventional research dose; converted at about 1.68 mcg per IU that is roughly 27-67 mcg, rounded to 25-70 mcg. That literature is acute, single-dose, and its replication record is contested; chronic self-administration has not been studied at all. There is no controlled human data for subcutaneous wellness dosing, so the subq route is listed because it is what grey-market users actually do, not because a dose has been established for it. Practical notes: a 10 mg vial is enormously more than any documented dose. Even reconstituted in 5 mL, a 40 mcg dose is about 2 units on a U-100 syringe, which is at the edge of what can be drawn accurately - the 10 mg presentation is really sized for making up a nasal spray rather than for single subcutaneous draws. Plasma half-life is a few minutes, so no hourly figure is listed. The scheduler stores this as daily only because that is the closest available slot; the effect is acute and short-lived and typical off-label use is per occasion, not a fixed daily course.

PT-141 (Bremelanotide)

A melanocortin receptor agonist approved by the FDA in 2019 as Vyleesi for acquired, generalised hypoactive sexual desire disorder in premenopausal women. The label dose is 1.75 mg (1750 mcg) subcutaneously into the abdomen or thigh, taken AS NEEDED at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than 8 doses per month. Phase 2 dose-ranging also studied 0.75 and 1.25 mg, which is where the 750 mcg floor here comes from; nothing above the 1.75 mg label dose is supported. IMPORTANT: this is not a scheduled compound. The scheduler stores it as 2x-week purely because that is the closest available slot to the label ceiling of 8 doses per month - do not read it as an instruction to dose on fixed days. Dose only before intended activity. The label contraindicates use in uncontrolled hypertension or known cardiovascular disease, a flag this dataset has no field for, so check blood pressure before starting. Efficacy in men is not established; use outside premenopausal women is off-label. The original intranasal formulation was abandoned in development after blood pressure increases, so the nasal route listed here reflects grey-market products, not an approved presentation.